Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
729 people get GTXI articles and Market Currents by email alert.
Get email alerts on GTXI »
FOCUS
|
PRO
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
-
-
-
-
-
-
GTx Has to Reevaluate Options Following Prostate Cancer Drug FailureEP Vantage • Thu, May 27, 2010 -
-
Does GTx Have the Muscle for Growth?Anthony Payne • Thu, Feb 22, 2007
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
6 Cash-Heavy Biotech Stocks With Analyst EndorsementsZetaKap • Thu, Aug 23, 2012 -
-
6 Biotech Stocks That Analysts Give The Green LightZetaKap • Fri, Jul 27, 2012
-
-
-
-
-
-
-
-
-
Insider Buys And Sells: Corning, Cabela'sAsif Suria • Mon, Mar 12, 2012 -
-
-
-
-
GTx's CEO Hosts Analyst Day Conference (Transcript)Fri, Feb 15 • 1 Comment
-
GTx's CEO Discusses Q2 2012 Results - Earnings Call TranscriptWed, Aug 8, 2012 • 1 Comment
-
GTx Inc Q4 2008 Earnings Call TranscriptTue, Feb 17, 2009
-
GTx, Inc. Q3 2008 Earnings Call TranscriptWed, Nov 19, 2008
-
GTx, Inc. Q2 2008 Earnings Call TranscriptMon, Sep 8, 2008
-
GTx Inc. Q1 2008 Earnings Call TranscriptMon, May 12, 2008
-
GTx Q4 2007 Earnings Call TranscriptTue, Feb 19, 2008
-
Business Wire (May 29, 2013)
-
Business Wire (May 3, 2013)
-
Business Wire (Apr 30, 2013)
-
Business Wire (Apr 19, 2013)
-
Business Wire (Apr 15, 2013)
-
Business Wire (Feb 27, 2013)
-
Business Wire (Feb 21, 2013)
-
Business Wire (Feb 19, 2013)
-
Business Wire (Feb 14, 2013)
-
Business Wire (Feb 12, 2013)
-
Business Wire (Feb 7, 2013)
-
Business Wire (Feb 5, 2013)
-
Business Wire (Dec 17, 2012)
-
Business Wire (Nov 8, 2012)
-
Business Wire (Nov 8, 2012)
GTXI vs. ETF Alternatives
Company Description
GTx, Inc., a Delaware corporation incorporated on September 24, 1997, is a biopharmaceutical company dedicated to the discovery, development and commercialization of small molecules that selectively target hormone pathways to treat cancer, osteoporosis and bone loss, muscle loss and other... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Friday, May 3, 6:41 AM GTX (GTXI): Q1 EPS of -$0.20 beats by $0.01. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Friday, May 3, 12:05 AM Notable earnings before Friday’s open: ADP, AXL, BBEP, BPL, CBOE, DUK, FBN, GBDC, GTXI, HST, LNT, MCO, NGLS, NRF, NVE, NWL, PNW, POM, PPC, REGN, SE, SEP, SMP, UPL, WCG, XLS, YRCW Comment! [Earnings]
- Thursday, May 2, 5:30 PM Notable earnings before Friday’s open: ADP, AXL, BBEP, BPL, CBOE, DUK, FBN, GBDC, GTXI, HST, LNT, MCO, NGLS, NRF, NVE, NWL, PNW, POM, PPC, REGN, SE, SEP, SMP, UPL, WCG, XLS, YRCW Comment! [Earnings]
-
Monday, April 15, 8:01 AM
GTx (GTXI) says two Phase III clinicals of Enobosarm will continue after a planned safety review. The company is compiling an "extensive safety database" as clinical trials progress for the company's cancer-related muscle deterioration treatment which was given Fast Track designation by the FDA in January. GTXI plans to file for marketing approval in Q3. Stifel Nicolaus calls the drug a "significant value-creating event."
Comment! [Healthcare] - Friday, April 5, 2:48 PM Cancer-focused biotech GTx (GTXI +7.1%) moves higher on double its 10-day average volume after Stifel Nicolaus initiates coverage with a Buy rating citing "a potentially significant value-creating event … with the pending Enobosarm Phase 3 data." Price target is $7, representing a 40% upside from the stock's current price. 1 Comment [Healthcare, On the Move]
- Thursday, February 21, 6:33 AM GTX (GTXI): Q4 EPS of -$0.17 beats by $0.05. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Thursday, February 21, 12:05 AM Notable earnings before Thursday’s open: AYR, CHK, CMS, DAN, DDS, DNR, ESV, FAF, FNP, GTXI, HEP, HNZ, HRL, HST, IMAX, IRC, LINE, LXP, PCG, PEG, PKD, PWR, PXP, SCG, SFL, SFY, SUI, SWY, TASR, THI, TK, TNK, WMT, WPRT, ZLC Comment! [Earnings]
- Wednesday, February 20, 5:30 PM Notable earnings before Thursday’s open: AYR, CHK, CMS, DAN, DDS, DNR, ESV, FAF, FNP, GTXI, HEP, HNZ, HRL, HST, IMAX, IRC, LINE, LXP, PCG, PEG, PKD, PWR, PXP, SCG, SFL, SFY, SUI, SWY, TASR, THI, TK, TNK, WMT, WPRT, ZLC Comment! [Earnings]
- Wednesday, January 9, 1:01 PM GTx Inc. (GTXI +5.7%) regains some lost traction from yesterday after the company reported that its drug, enobosarm, which is indicated for the prevention and treatment of muscle wasting in patients with non-small cell lung cancer, has been given a Fast Track designation by the FDA. Comment! [Healthcare, On the Move]
-
Tuesday, January 8, 5:40 PM
After-hours top gainers, as of 5:15 p.m.: STX +3%. GTXI +2%. JRCC +2%. GPN +2%. ODP +2%.
After-hours top losers: APOL -4%. S -3%. CREE -3%. CLDT -2%. PZE -2%. 1 Comment [On the Move] -
Tuesday, December 11, 2012, 12:45 PM
Midday top 10 gainers: BGMD +146%. SOMX +75%. ACUR +56%. TNS +43%. ULBI +18%. MEAD +16%. ESYS +15%. SZYM +14%. GTXI +13%. CLWR +12%.
Midday top 10 Losers: CBMX -11%. ESIO -11%. AMCN -9%. SEV -9%. GGAL -8%. SPW -8%. TELK -7%. [[JW-A]] -7%. MGLN -7%. SXC -7%. 2 Comments [On the Move] - Thursday, November 8, 2012, 6:41 AM GTx (GTXI): Q3 EPS of -$0.08 beats by $0.10. (PR) Comment! [Earnings, Healthcare]
- Thursday, November 8, 2012, 12:05 AM Notable earnings before Thursday’s open: AAP, AINV, AMRC, APU, BCRX, CNQ, DF, DUK, EBIX, ES, EZCH, FE, FSYS, GTXI, HK, KIOR, KSS, MFC, MWW, NOG, PGNX, PMT, POZN, PPL, SMBL, SNSS, SVNT, THI, TNK, VMC, WEN, WIN Comment! [Earnings]
- Wednesday, November 7, 2012, 5:30 PM Notable earnings before Thursday’s open: AAP, AINV, AMRC, APU, BCRX, CNQ, DF, DUK, EBIX, ES, EZCH, FE, FSYS, GTXI, HK, KIOR, KSS, MFC, MWW, NOG, PGNX, PMT, POZN, PPL, SMBL, SNSS, SVNT, THI, TNK, VMC, WEN, WIN 1 Comment [Earnings]
- Wednesday, August 8, 2012, 6:37 AM GTx (GTXI): Q2 EPS of -$0.17 in-line. Revenue of $1.64M misses by $0.6M. (PR) Comment! [Earnings, Healthcare]
- Tuesday, May 8, 2012, 8:35 AM GTx (GTXI) +10.3% premarket after saying the FDA removed its Full Clinical Hold on its Investigational New Drug application for prostate cancer treatment Capesaris. During Q3, GTXI expects to initiate a Phase II clinical study of Capesaris as a secondary hormonal therapy in men with certain kinds of prostate cancer. (also: earnings) Comment! [Healthcare, On the Move]
Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.